Novo Nordisk's adjusted operating profit reac...

Headline growth is a mirage—underlying sales and profit are actually shrinking.

What the company is saying

Novo Nordisk is positioning itself as a global healthcare leader delivering breakthrough obesity and diabetes treatments, with a narrative centered on innovation, scale, and market momentum. The company wants investors to focus on the 'strongest-ever' GLP-1 launch in US history, the rapid uptake of the Wegovy pill, and a raised 2026 outlook driven by GLP-1 product sales. Management highlights headline figures like a 32% reported sales increase and a 65% jump in reported operating profit, both at constant exchange rates (CER), while attributing these to successful product launches and operational excellence. However, the announcement buries the fact that these headline numbers are inflated by a one-time USD 4.2 billion provision reversal related to the US 340B Drug Pricing Program, and that adjusted sales and operating profit actually declined. The tone is upbeat and confident, using superlatives such as 'strongest-ever' and emphasizing regulatory wins and pipeline progress, but it selectively downplays the negative underlying trends. Mike Doustdar, identified as president and CEO, is the only notable individual with a clear institutional role; his involvement is expected and does not add external validation. The communication style fits Novo Nordisk’s established investor relations approach: highlight innovation and global reach, minimize discussion of operational headwinds, and frame guidance downgrades as 'raised' outlooks. Compared to prior communications (where history is unavailable), the messaging here leans heavily on product success and headline growth, while the negative underlying trajectory is only visible in the fine print.

What the data suggests

The disclosed numbers show a stark contrast between headline and underlying performance. Reported net sales for Q1 2026 were DKK 96,823 million, up 32% at CER, and reported operating profit was DKK 59,618 million, up 65% at CER. However, these figures are distorted by a one-off USD 4.2 billion provision reversal, which is not part of recurring business operations. Adjusted net sales, which exclude this reversal, actually declined by 4% at CER (to DKK 70,063 million), and adjusted operating profit fell by 6% at CER (to DKK 32,858 million). US operations were particularly weak, with adjusted sales down 11% at CER, only partly offset by a 6% increase in international sales. Obesity care sales (adjusted) rose 22% at CER, but the absolute value is not disclosed, making it hard to assess the true scale. The company’s own 2026 guidance expects further declines: adjusted sales and operating profit are both forecast to shrink by 4% to 12% at CER. The financial disclosures are clear about the impact of the provision reversal and provide both reported and adjusted figures, but lack granularity in some segments and pipeline claims. An independent analyst would conclude that, absent the one-time gain, Novo Nordisk’s core business is contracting, and the positive narrative is not supported by recurring financial performance.

Analysis

The announcement's tone is upbeat, highlighting strong product launches and headline growth figures. However, much of the reported growth is attributable to a one-time USD 4.2 billion provision reversal, which inflates reported sales and operating profit. When this is excluded, adjusted sales and operating profit actually declined, and the company's forward guidance anticipates further declines in 2026. Most claims are realised and supported by numerical data, with only a small fraction being forward-looking projections (e.g., international Wegovy pill launches and 2026 outlook). The language is somewhat inflated by emphasizing 'strongest-ever' launches and headline growth, despite underlying declines. There is no evidence of a large new capital outlay with long-dated returns, and most benefits are either realised or expected within the next 6-24 months. The gap between narrative and evidence is moderate: the company is transparent about the provision reversal, but the positive framing of underlying declines and selective focus on product successes over broader financial weakness inflates the overall signal.

Risk flags

• ●Headline growth is driven by a one-time USD 4.2 billion provision reversal, not by recurring business performance. This distorts the true financial trajectory and could mislead investors about the sustainability of current results.
• ●Adjusted sales and operating profit are both declining (down 4% and 6% at CER, respectively), indicating underlying business weakness. If this trend continues, it could erode investor confidence and pressure the share price.
• ●US operations, historically the company’s largest and most profitable market, saw an 11% decline in adjusted sales at CER. This suggests pricing pressure or competitive challenges that may persist or worsen.
• ●The company’s raised 2026 outlook is still for negative growth (-4% to -12% at CER for both sales and operating profit), which is a red flag for future earnings potential. Positive framing of a negative outlook can mask deteriorating fundamentals.
• ●Some product and pipeline claims (e.g., zenagamtide AMAZE phase 3 initiation, Awiqli FDA approval, etavopivat trial success) lack numerical or date evidence, making it difficult to independently verify progress or impact.
• ●Segment-level financial granularity is missing, especially for Obesity care sales, which are only reported as a growth rate without absolute values. This limits the ability to assess the true drivers of performance.
• ●The company’s narrative relies heavily on recent product launches and superlative claims (e.g., 'strongest-ever' GLP-1 launch), which may not translate into sustainable, recurring revenue if initial demand is not maintained.
• ●Execution risk is elevated for international Wegovy pill launches, as these are contingent on regulatory approvals and market uptake in the second half of 2026. Delays or underperformance in these launches could further pressure results.

Bottom line

For investors, this announcement means that Novo Nordisk’s headline growth is largely an accounting artifact, not a sign of underlying business strength. The company is transparent about the one-time provision reversal, but the positive narrative around product launches and prescription volumes cannot mask the fact that adjusted sales and operating profit are both shrinking. There is no evidence of external institutional validation beyond the expected involvement of the CEO, so no additional credibility is conferred. To change this assessment, Novo Nordisk would need to deliver recurring, organic growth in adjusted sales and profit, and provide more granular segment data to clarify the true drivers of performance. Key metrics to watch in the next reporting period include adjusted sales and operating profit (excluding one-offs), US and international segment trends, and the sustainability of prescription volumes for new products. Investors should treat this announcement as a weak positive signal at best—worth monitoring for signs of a turnaround, but not a basis for new investment unless underlying trends improve. The single most important takeaway is that, despite the upbeat tone and headline numbers, Novo Nordisk’s core business is currently in decline and the outlook for 2026 is negative.

Announcement summary

Novo Nordisk reported that its adjusted operating profit reached DKK 32,858 million in Q1 2026. Reported sales increased by 32% at CER, while adjusted sales excluding a provision reversal decreased by 4% at CER. The Wegovy® pill was launched in the US on 5 January 2026, with total weekly prescriptions exceeding 200,000 for the week ending 17 April and around 1.3 million total prescriptions in Q1 2026. The company raised its 2026 outlook, now expecting adjusted sales and operating profit growth of -4 to -12% at CER. These results are significant for investors as they reflect strong product launches and revised financial guidance.

Disagree with this article?